Donegan Michael C 4

4 · TherapeuticsMD, Inc. · Filed Jan 30, 2023

Form 4

Period: 2023-01-26

Vice President Finance

Transactions

Sale
Common Stock
2023-01-26$5.08/sh−1,648$8,371→ 11,902 total
Exercise/Conversion
Performance Stock Units
2023-01-26−2,400→ 0 total
Exercise: $0.00→ Common Stock (2,400 underlying)
Exercise/Conversion
Common Stock
2023-01-26+2,400→ 12,410 total
Sale
Common Stock
2023-01-27$5.09/sh−49$249→ 11,853 total
Exercise/Conversion
Common Stock
2023-01-26+1,140→ 13,550 total
Exercise/Conversion
Common Stock
2023-01-26+2,400→ 10,010 total
Exercise/Conversion
Performance Stock Units
2023-01-26−2,400→ 0 total
Exercise: $0.00→ Common Stock (2,400 underlying)
Exercise/Conversion
Performance Stock Units
2023-01-26−1,140→ 0 total
Exercise: $0.00→ Common Stock (1,140 underlying)

Footnotes (4)

[F1]Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).
[F2]The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
[F4]Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

Documents

1 file